Nexgard Spectra Spot-On for Cats 0.8 – 2.4 kg and Nexgard Spectra Spot-On for Cats 2.5 – 7.5 kg containing esafoxolaner

This consultation closed on 14 February 2023

Consultation period

24 January 2023 to 14 February 2023

The APVMA is considering an application for approval of the new active constituent, esafoxolaner, and registration of the products, Nexgard Spectra Spot-On for Cats 0.8 – 2.4 kg and Nexgard Spectra Spot-On for Cats 2.5 – 7.5 kg, containing 12 g/L esafoxolaner (1.2% w/v), 83 g/L praziquantel (8.3% w/v) and 4 g/L eprinomectin (0.4% w/v). The product is used for the treatment and prevention of flea infestations, control of ticks and mites, prevention of heartworm disease, and treatment and control of intestinal worms in cats and kittens from 8 weeks of age.

We invite comments from 24 January 2023 to 14 February 2023 on whether approval of the active constituent and registration of the product should be granted.

The APVMA is able to consider comments relating to the legislative grounds, including:

  • chemistry and manufacture
  • occupational health and safety
  • public health
  • environmental safety
  • efficacy and target animal safety.

For more information see page 17, APVMA Gazette No. 2, 24 January 2023.

Please note: Submissions will be published on the APVMA’s website unless you have asked for the submission to remain confidential (see public submission coversheet). 

Please lodge your submission with a public submission coversheet, which provides options for how your submission will be published.

Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.

Please send your written submission and coversheet by email or post to:

Case Management and Administration Unit
Australian Pesticides and Veterinary Medicines Authority
GPO Box 3262
Sydney NSW 2001
Phone: +61 2 6770 2300


Was this page helpful?

Your feedback will be submitted to the APVMA anonymously. If you require a response, please contact us.